Survey shows most lack education about genomics
SALT LAKE CITY, UTAH, USA, June 19, 2018 /EINPresswire.com/ — Precision medicine is changing the way patients receive care and is viewed as the future of medicine by many; yet as we move into that future, awareness is still lacking. Results from a recent survey by GenomeWeb and the Personalized Medicine Coalition showed Americans are unfamiliar with precision medicine.
The online survey asked 1,001 adults representative of the U.S. population various questions about their awareness on the topic. The results showed a lack of education on what genomics is and what it can do for their personal care. However, when they were taught more about precision medicine, they were excited about the possibilities. Intermountain is dedicated to educating the public and providing clinical implementation to its patients.
Precision medicine considers individual factors to decide the best route of treatment for each specific patient.
Intermountain Healthcare’s care process model of clinical implementation of precision medicine can provide patients the best care through use of new technology. According, Tyler Haberle, MD, FACP, medical director for Intermountain Healthcare’s Care Transformation Services, “Intermountain Precision Genomics has already started engaging with primary care, behavioral health, and Care Transformation Services to deliver, not just the clinical care and laboratory results, but an EMR (Electronic Medical Record) solution that augments care – rather than interrupts or adds cognitive burden.”
Lincoln Nadauld, MD, PhD, executive director of Intermountain Precision Genomics and Precision Medicine says, “Our team at Intermountain continues to see promise in the application of precision medicine and its ability to deliver better outcomes.” Nadauld adds, “We are particularly excited about the use of precision medicine across medical disciplines, including cancer, cardiovascular medicine, mental health and neurological disorders.”
Intermountain Precision Genomics (IPG) provides an array of personalized genomic solutions for patient care. RxMatch™ comprehensive drug panel has the potential to match the right dosage and medication based on a patient’s DNA. The unique ICG100™ test for cancer mutations and the newly released Heredigene™ test to identify risk for hereditary breast cancer.
email us here
Source: EIN Presswire